Novo Nordisk

February 19, 2025 4:45 PM

Fat, not muscle: drugmakers in race for next weight-loss breakthrough

Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can increase the risk of falls and decrease overall strength, which could be especially harmful for older patients. The following companies are developing weight-loss treatments that help preserve or grow muscles while patients shed pounds: Eli Lilly The U.S. drugmaker spent nearly $2 billion in 2023 to acquire Versan...

December 20, 2024 5:22 PM

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value. The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company's ambitions for a successor to its popular Wegovy that is more powerful than Eli Lilly's rival Zepbound, also known as Mounjaro. Investors and analysts had eagerly awaite...

December 2, 2024 4:30 PM

4 oral GLP-1R obesity drugs in race for approval, Novo Nordisk leads: report

Four oral glucagon-like peptide-1 receptor (GLP-1R) drugs, currently under Phase III trials, are in the race for approval, according to a report. This follows the immense popularity of injectable GLP-1R drugs, such as Novo Nordisk’s Wegovy and Saxenda, Eli Lilly’s Zepbound, and Shanghai Benemae Pharmaceutical’s Yishengtai, all of which have been approved for obesity. The report by GlobalData, a data and analytics company, showed that 63 drugs are in active development, with four Phase II...

October 15, 2024 7:25 PM

Britain to study use of weight loss drug to get people back to work

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation, after Lilly announced a 279 million pound ($365 million) investment in Britain as part of a flagship summit hosted by Prime Minister Keir Starmer. The dea...

September 11, 2024 4:36 PM

Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial

Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects. The maker of blockbuster drugs Wegovy and Ozempic said in March that a Phase I trial of the pill version of amycretin showed participants lost up to 13.1% of their weight after 12 weeks, prompting shares to surge more than 8%. That compared to weight loss of about 6% after 12 weeks and 15% after 68 we...

August 15, 2024 4:07 PM

Doctors struggle to get Wegovy for older Americans with heart disease

Older Americans are having little success getting prescriptions for weight-loss drug Wegovy covered by Medicare despite the federal healthcare program's decision to pay for patients with obesity at risk of heart disease, according to their doctors. In interviews with Reuters, seven obesity and heart disease specialists from various parts of the United States said their prescriptions for the Novo Nordisk drug have been denied repeatedly by the healthcare companies that administer Medicare drug b...

July 30, 2024 3:52 PM

Ozempic linked to less tobacco-related healthcare use in study

Smokers with type 2 diabetes taking Novo Nordisk’s Ozempic had fewer tobacco-related medical encounters and fewer interventions to help them quit smoking than those who received other diabetes drugs, according to a study of electronic health records published on Monday. In the year after starting treatment, Ozempic users with a previous diagnosis of tobacco use disorder were up to 32% less likely to discuss tobacco use with a healthcare provider than those taking other diabetes medications. T...

July 11, 2024 7:32 PM

Pfizer moves forward with once-daily weight-loss pill

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice- daily version of the drug late last year. The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections. Some analysts expect the weight-loss drug market, currently dominated ...

July 9, 2024 4:57 PM

Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss

Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss. The analysis was published on Monday in JAMA Internal Medicine, a medical journal. It examined health records and other data to assess the pace and percentage of weight loss for overweight and obese people taking tirzepatide - the active ingredient in Lilly's Mounjaro a...